{"title":"Pre-transplantation levels of lysine (K)-specific methyltransferase 2A (<i>KMT2A</i>) partial tandem duplications can predict relapse of acute myeloid leukemia patients following haploidentical donor hematopoietic stem cell transplantation.","authors":"Dao-Xing Deng, Xiao-Hang Ma, Ze-Hua Wu, Xiao-Hui Zhang, Lan-Ping Xu, Yu Wang, Chen-Hua Yan, Huan Chen, Yu-Hong Chen, Wei Han, Feng-Rong Wang, Jing-Zhi Wang, Xiao-Jun Huang, Xiao-Su Zhao, Xiao-Dong Mo","doi":"10.1097/BS9.0000000000000207","DOIUrl":null,"url":null,"abstract":"<p><p>We aimed to identify dynamic changes of lysine (K)-specific methyltransferase 2A partial tandem duplications (<i>KMT2A</i>-PTD) before and after haploidentical donor hematopoietic stem cell transplantation (HID HSCT) and explore the prognostic value of pre-transplantation levels of <i>KMT2A</i>-PTD in acute myeloid leukemia (AML) receiving HID HSCT. Consecutive 64 AML patients with <i>KMT2A</i>-PTD positivity at diagnosis receiving HID HSCT were included in this study. Patients with <i>KMT2A</i>-PTD ≥1% before HSCT had a slower decrease of <i>KMT2A</i>-PTD after HID HSCT. Patients with <i>KMT2A</i>-PTD ≥1% before HID HSCT had a higher cumulative incidence of relapse (36.4%, 95% confidence interval [CI]: 6.3%-66.5%) at 2 years after HSCT than those with <i>KMT2A</i>-PTD <1% (7.5%, 95% CI: 0.3%-14.7%, <i>P</i> = .010). In multivariable analysis, <i>KMT2A</i>-PTD ≥1% before HID HSCT was the only independent risk factor for relapse (hazard ratio [HR]: 4.90; 95% CI: 1.22-19.59; <i>P</i> = .025). Thus, pre-transplantation levels of <i>KMT2A</i>-PTD could predict relapse in AML patients following HID HSCT.</p>","PeriodicalId":67343,"journal":{"name":"血液科学(英文)","volume":"6 4","pages":"e00207"},"PeriodicalIF":1.5000,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11427034/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"血液科学(英文)","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/BS9.0000000000000207","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
We aimed to identify dynamic changes of lysine (K)-specific methyltransferase 2A partial tandem duplications (KMT2A-PTD) before and after haploidentical donor hematopoietic stem cell transplantation (HID HSCT) and explore the prognostic value of pre-transplantation levels of KMT2A-PTD in acute myeloid leukemia (AML) receiving HID HSCT. Consecutive 64 AML patients with KMT2A-PTD positivity at diagnosis receiving HID HSCT were included in this study. Patients with KMT2A-PTD ≥1% before HSCT had a slower decrease of KMT2A-PTD after HID HSCT. Patients with KMT2A-PTD ≥1% before HID HSCT had a higher cumulative incidence of relapse (36.4%, 95% confidence interval [CI]: 6.3%-66.5%) at 2 years after HSCT than those with KMT2A-PTD <1% (7.5%, 95% CI: 0.3%-14.7%, P = .010). In multivariable analysis, KMT2A-PTD ≥1% before HID HSCT was the only independent risk factor for relapse (hazard ratio [HR]: 4.90; 95% CI: 1.22-19.59; P = .025). Thus, pre-transplantation levels of KMT2A-PTD could predict relapse in AML patients following HID HSCT.